| Sex and management of rheumatoid arthritis EG Favalli, M Biggioggero, C Crotti, A Becciolini, MG Raimondo, ... Clinical reviews in allergy & immunology 56, 333-345, 2019 | 203 | 2019 |
| Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection M Biggioggero, C Crotti, A Becciolini, EG Favalli Drug design, development and therapy, 57-70, 2018 | 157 | 2018 |
| Profile of sarilumab and its potential in the treatment of rheumatoid arthritis MG Raimondo, M Biggioggero, C Crotti, A Becciolini, EG Favalli Drug Design, Development and Therapy, 1593-1603, 2017 | 127 | 2017 |
| The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives EG Favalli, MG Raimondo, A Becciolini, C Crotti, M Biggioggero, ... Autoimmunity reviews 16 (12), 1185-1195, 2017 | 97 | 2017 |
| Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis F Cantini, L Niccoli, C Nannini, E Cassarà, O Kaloudi, EG Favalli, ... Seminars in arthritis and rheumatism 47 (2), 183-192, 2017 | 89 | 2017 |
| Twelve‐year retention rate of first‐line tumor necrosis factor inhibitors in rheumatoid arthritis: real‐life data from a local registry EG Favalli, F Pregnolato, M Biggioggero, A Becciolini, AE Penatti, ... Arthritis care & research 68 (4), 432-439, 2016 | 85 | 2016 |
| The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting M Di Carlo, A Becciolini, V Lato, C Crotti, EG Favalli, F Salaffi The Journal of rheumatology 44 (3), 279-285, 2017 | 80 | 2017 |
| Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study M Varenna, F Zucchi, S Failoni, A Becciolini, M Berruto Rheumatology 54 (10), 1826-1832, 2015 | 73 | 2015 |
| Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis M Biggioggero, A Becciolini, C Crotti, E Agape, EG Favalli Drugs in context 8, 2019 | 67 | 2019 |
| Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis F Cantini, L Niccoli, C Nannini, E Cassara, O Kaloudi, EG Favalli, ... Seminars in Arthritis and Rheumatism 45 (5), 519-532, 2016 | 62 | 2016 |
| Bone erosions in rheumatoid arthritis: ultrasound findings in the early stage of the disease MM Tămaş, E Filippucci, A Becciolini, M Gutierrez, L Di Geso, K Bonfiglioli, ... Rheumatology 53 (6), 1100-1107, 2014 | 58 | 2014 |
| Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects C Crotti, E Agape, A Becciolini, M Biggioggero, EG Favalli Drugs 79 (16), 1741-1755, 2019 | 57 | 2019 |
| Eight‐year retention rate of first‐line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis EG Favalli, C Selmi, A Becciolini, M Biggioggero, A Ariani, D Santilli, ... Arthritis Care & Research 69 (6), 867-874, 2017 | 46 | 2017 |
| Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult-and juvenile-onset populations: similarities and differences EG Favalli, I Pontikaki, A Becciolini, M Biggioggero, N Ughi, M Romano, ... Clinical rheumatology 36, 1747-1755, 2017 | 43 | 2017 |
| Interreader reliability in assessment of nailfold capillary abnormalities by beginners: pilot study of an intensive videocapillaroscopy training program M Gutierrez, C Bertolazzi, M Tardella, A Becciolini, M Di Carlo, M Dottori, ... The Journal of Rheumatology 39 (6), 1248-1255, 2012 | 34 | 2012 |
| Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from … EG Favalli, L Sinigaglia, A Becciolini, V Grosso, R Gorla, C Bazzani, ... International journal of rheumatic diseases 21 (2), 422-430, 2018 | 33 | 2018 |
| Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis C Crotti, M Biggioggero, A Becciolini, E Agape, EG Favalli Expert opinion on investigational drugs 28 (7), 573-581, 2019 | 32 | 2019 |
| The management of acute anterior uveitis complicating spondyloarthritis: present and future M Biggioggero, C Crotti, A Becciolini, E Miserocchi, EG Favalli BioMed research international 2018, 2018 | 28 | 2018 |
| Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date C Crotti, MG Raimondo, A Becciolini, M Biggioggero, EG Favalli Drug Design, Development and Therapy, 211-223, 2017 | 24 | 2017 |
| Sarilumab: patient-reported outcomes in rheumatoid arthritis C Crotti, M Biggioggero, A Becciolini, EG Favalli Patient Related Outcome Measures, 275-284, 2018 | 23 | 2018 |
